Diabetes Metabolic Syndrome and Obesity-Targets and Therapy-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2099883, encodeId=58722099883aa, content=偏重的研究方向：代谢综合征 经验分享：1DA - WAITING FOR THIRD PARTY BILLING INFORMATION 请问大家，这个状态下收到的邮件，那个链接好像没有可以操作的东西，请问大家当时是怎么处理的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70e46545621, createdName=秃头医学僧, createdTime=Fri Nov 11 14:02:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102656, encodeId=ff8b210265635, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：大血管并发症;糖尿病 经验分享：经验分享：审稿比较快，投稿后1个月左右就返修了，编辑提出的意见很中肯而且一针见血，按照编辑的修改意见逐条进行修改后，很快就接收见刊了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8445702010, createdName=ms8000000933790308, createdTime=Fri Nov 25 22:07:57 CST 2022, time=2022-11-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2104368, encodeId=43f521043681e, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病 经验分享：正在投稿中，等消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=903a2271475, createdName=121a6c8dm38(暂无昵称), createdTime=Mon Dec 05 10:21:54 CST 2022, time=2022-12-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2103276, encodeId=9b1821032e6b6, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病并发症 经验分享：这次有四个审稿人，但是都非常nice，所有流程如下： 27 July 2022 Submission created 4 August 2022 Peer review selection 4 August 2022 Peer review invitations sent 5 August 2022 First peer reviewer allocated 7 August 2022 Two or more peer reviewers allocated 18 August 2022 First report returned 6 September 2022 Second or more peer reviewer reports returned 27 September 2022 Report sent to the Editor-in-Chief 28 September 2022 Report: revise with changes 30 September 2022 Resubmission pending 13 October 2022 Resubmitted manuscript received 18 October 2022 Processing revised manuscript 19 October 2022 Sent to Editor-in-Chief for acceptance or rejection 18 October 2022 Query regarding revised manuscript 20 October 2022 Invoice to follow for article processing charge subject to final decision 21 October 2022 Accepted for publication, invoice sent 21 October 2022 Payment has been received 25 October 2022 Manuscript sent to typesetter for pre-edit. No action required from the author 26 October 2022 Manuscript with the typesetter for first proof creation or updates to the proof. No action required from the author 27 October 2022 Typeset page proofs sent to the author(s) for correction or approval. Please login using the link provided to submit the proof back to Editorial team 27 October 2022 Author has returned corrections 29 October 2022 Page proofs approved by the author. At this point the manuscript is ready for publication 29 October 2022 Page proofs approved by the author. Paper is on hold awaiting further information 29 October 2022 Manuscript is sent for page numbering at Typesetter 29 October 2022 Manuscript been returned from Typesetter with page numbers 29 October 2022 Online final version is published, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221129/0e7eeda129144fbba505acd961d4e564/9a1914f121264b1dbf789fd21a61dab6.jpg, createdBy=a67a5253380, createdName=ms954663428435720, createdTime=Tue Nov 29 14:09:31 CST 2022, time=2022-11-29, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2107203, encodeId=0979210e203df, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病并发症;糖尿病 经验分享：已经连续发表两篇了，审稿者提问还是很中肯的，能为我们写作提供帮助。希望能涨涨分。不知道今年中科院分区怎么样。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2821418776, createdName=elisha1986922, createdTime=Fri Dec 23 21:03:46 CST 2022, time=2022-12-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2097212, encodeId=7627209e212c1, content=返修后从4C到7I只有3天时间，请问各位大神，7I是不是就悲剧了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2fb2950730, createdName=312460187, createdTime=Sat Oct 29 08:40:04 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083547, encodeId=790c108354e11, content=偏重的研究方向：糖尿病 经验分享：最近我投了这个杂志，投稿14天已经有一个审稿意见回来了，感觉是不是要被拒了，有没有人分享经验？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2821418776, createdName=elisha1986922, createdTime=Thu Dec 23 15:06:01 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248658, encodeId=eaa41248658b9, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：氧化应激;糖尿病 经验分享：编辑很好，审稿也快，对SCI新手也很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a648175314, createdName=ms6000000147750690, createdTime=Tue Sep 13 15:04:17 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235020, encodeId=098012350207b, content=请问，录用到检索需要多久，有经验的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04ff6407559, createdName=ms2000000815129795, createdTime=Wed Jul 27 11:09:52 CST 2022, time=2022-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235628, encodeId=69dd12356286f, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：从投到最终接收不到五个月.编辑整体很nice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uLbZicGxVGAWXmCkrtzXibzr4ZBcjzaTNHjNnVEcERkDEgTeSeeHQtlg9mMhA5gbq1obJP80q1pYRxCgWUgTfQAQ/132, createdBy=04a75281899, createdName=runze4922, createdTime=Sat Jul 30 13:15:55 CST 2022, time=2022-07-30, status=1, ipAttribution=)]

2022-11-11 秃头医学僧

偏重的研究方向：代谢综合征
经验分享：1DA - WAITING FOR THIRD PARTY BILLING INFORMATION 请问大家，这个状态下收到的邮件，那个链接好像没有可以操作的东西，请问大家当时是怎么处理的呢

48 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2099883, encodeId=58722099883aa, content=偏重的研究方向：代谢综合征 经验分享：1DA - WAITING FOR THIRD PARTY BILLING INFORMATION 请问大家，这个状态下收到的邮件，那个链接好像没有可以操作的东西，请问大家当时是怎么处理的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70e46545621, createdName=秃头医学僧, createdTime=Fri Nov 11 14:02:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102656, encodeId=ff8b210265635, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：大血管并发症;糖尿病 经验分享：经验分享：审稿比较快，投稿后1个月左右就返修了，编辑提出的意见很中肯而且一针见血，按照编辑的修改意见逐条进行修改后，很快就接收见刊了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8445702010, createdName=ms8000000933790308, createdTime=Fri Nov 25 22:07:57 CST 2022, time=2022-11-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2104368, encodeId=43f521043681e, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病 经验分享：正在投稿中，等消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=903a2271475, createdName=121a6c8dm38(暂无昵称), createdTime=Mon Dec 05 10:21:54 CST 2022, time=2022-12-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2103276, encodeId=9b1821032e6b6, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病并发症 经验分享：这次有四个审稿人，但是都非常nice，所有流程如下： 27 July 2022 Submission created 4 August 2022 Peer review selection 4 August 2022 Peer review invitations sent 5 August 2022 First peer reviewer allocated 7 August 2022 Two or more peer reviewers allocated 18 August 2022 First report returned 6 September 2022 Second or more peer reviewer reports returned 27 September 2022 Report sent to the Editor-in-Chief 28 September 2022 Report: revise with changes 30 September 2022 Resubmission pending 13 October 2022 Resubmitted manuscript received 18 October 2022 Processing revised manuscript 19 October 2022 Sent to Editor-in-Chief for acceptance or rejection 18 October 2022 Query regarding revised manuscript 20 October 2022 Invoice to follow for article processing charge subject to final decision 21 October 2022 Accepted for publication, invoice sent 21 October 2022 Payment has been received 25 October 2022 Manuscript sent to typesetter for pre-edit. No action required from the author 26 October 2022 Manuscript with the typesetter for first proof creation or updates to the proof. No action required from the author 27 October 2022 Typeset page proofs sent to the author(s) for correction or approval. Please login using the link provided to submit the proof back to Editorial team 27 October 2022 Author has returned corrections 29 October 2022 Page proofs approved by the author. At this point the manuscript is ready for publication 29 October 2022 Page proofs approved by the author. Paper is on hold awaiting further information 29 October 2022 Manuscript is sent for page numbering at Typesetter 29 October 2022 Manuscript been returned from Typesetter with page numbers 29 October 2022 Online final version is published, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221129/0e7eeda129144fbba505acd961d4e564/9a1914f121264b1dbf789fd21a61dab6.jpg, createdBy=a67a5253380, createdName=ms954663428435720, createdTime=Tue Nov 29 14:09:31 CST 2022, time=2022-11-29, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2107203, encodeId=0979210e203df, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病并发症;糖尿病 经验分享：已经连续发表两篇了，审稿者提问还是很中肯的，能为我们写作提供帮助。希望能涨涨分。不知道今年中科院分区怎么样。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2821418776, createdName=elisha1986922, createdTime=Fri Dec 23 21:03:46 CST 2022, time=2022-12-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2097212, encodeId=7627209e212c1, content=返修后从4C到7I只有3天时间，请问各位大神，7I是不是就悲剧了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2fb2950730, createdName=312460187, createdTime=Sat Oct 29 08:40:04 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083547, encodeId=790c108354e11, content=偏重的研究方向：糖尿病 经验分享：最近我投了这个杂志，投稿14天已经有一个审稿意见回来了，感觉是不是要被拒了，有没有人分享经验？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2821418776, createdName=elisha1986922, createdTime=Thu Dec 23 15:06:01 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248658, encodeId=eaa41248658b9, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：氧化应激;糖尿病 经验分享：编辑很好，审稿也快，对SCI新手也很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a648175314, createdName=ms6000000147750690, createdTime=Tue Sep 13 15:04:17 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235020, encodeId=098012350207b, content=请问，录用到检索需要多久，有经验的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04ff6407559, createdName=ms2000000815129795, createdTime=Wed Jul 27 11:09:52 CST 2022, time=2022-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235628, encodeId=69dd12356286f, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：从投到最终接收不到五个月.编辑整体很nice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uLbZicGxVGAWXmCkrtzXibzr4ZBcjzaTNHjNnVEcERkDEgTeSeeHQtlg9mMhA5gbq1obJP80q1pYRxCgWUgTfQAQ/132, createdBy=04a75281899, createdName=runze4922, createdTime=Sat Jul 30 13:15:55 CST 2022, time=2022-07-30, status=1, ipAttribution=)]

2022-11-25 ms8000000933790308 来自浙江省

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：大血管并发症;糖尿病
经验分享：经验分享：审稿比较快，投稿后1个月左右就返修了，编辑提出的意见很中肯而且一针见血，按照编辑的修改意见逐条进行修改后，很快就接收见刊了。

51 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2099883, encodeId=58722099883aa, content=偏重的研究方向：代谢综合征 经验分享：1DA - WAITING FOR THIRD PARTY BILLING INFORMATION 请问大家，这个状态下收到的邮件，那个链接好像没有可以操作的东西，请问大家当时是怎么处理的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70e46545621, createdName=秃头医学僧, createdTime=Fri Nov 11 14:02:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102656, encodeId=ff8b210265635, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：大血管并发症;糖尿病 经验分享：经验分享：审稿比较快，投稿后1个月左右就返修了，编辑提出的意见很中肯而且一针见血，按照编辑的修改意见逐条进行修改后，很快就接收见刊了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8445702010, createdName=ms8000000933790308, createdTime=Fri Nov 25 22:07:57 CST 2022, time=2022-11-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2104368, encodeId=43f521043681e, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病 经验分享：正在投稿中，等消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=903a2271475, createdName=121a6c8dm38(暂无昵称), createdTime=Mon Dec 05 10:21:54 CST 2022, time=2022-12-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2103276, encodeId=9b1821032e6b6, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病并发症 经验分享：这次有四个审稿人，但是都非常nice，所有流程如下： 27 July 2022 Submission created 4 August 2022 Peer review selection 4 August 2022 Peer review invitations sent 5 August 2022 First peer reviewer allocated 7 August 2022 Two or more peer reviewers allocated 18 August 2022 First report returned 6 September 2022 Second or more peer reviewer reports returned 27 September 2022 Report sent to the Editor-in-Chief 28 September 2022 Report: revise with changes 30 September 2022 Resubmission pending 13 October 2022 Resubmitted manuscript received 18 October 2022 Processing revised manuscript 19 October 2022 Sent to Editor-in-Chief for acceptance or rejection 18 October 2022 Query regarding revised manuscript 20 October 2022 Invoice to follow for article processing charge subject to final decision 21 October 2022 Accepted for publication, invoice sent 21 October 2022 Payment has been received 25 October 2022 Manuscript sent to typesetter for pre-edit. No action required from the author 26 October 2022 Manuscript with the typesetter for first proof creation or updates to the proof. No action required from the author 27 October 2022 Typeset page proofs sent to the author(s) for correction or approval. Please login using the link provided to submit the proof back to Editorial team 27 October 2022 Author has returned corrections 29 October 2022 Page proofs approved by the author. At this point the manuscript is ready for publication 29 October 2022 Page proofs approved by the author. Paper is on hold awaiting further information 29 October 2022 Manuscript is sent for page numbering at Typesetter 29 October 2022 Manuscript been returned from Typesetter with page numbers 29 October 2022 Online final version is published, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221129/0e7eeda129144fbba505acd961d4e564/9a1914f121264b1dbf789fd21a61dab6.jpg, createdBy=a67a5253380, createdName=ms954663428435720, createdTime=Tue Nov 29 14:09:31 CST 2022, time=2022-11-29, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2107203, encodeId=0979210e203df, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病并发症;糖尿病 经验分享：已经连续发表两篇了，审稿者提问还是很中肯的，能为我们写作提供帮助。希望能涨涨分。不知道今年中科院分区怎么样。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2821418776, createdName=elisha1986922, createdTime=Fri Dec 23 21:03:46 CST 2022, time=2022-12-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2097212, encodeId=7627209e212c1, content=返修后从4C到7I只有3天时间，请问各位大神，7I是不是就悲剧了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2fb2950730, createdName=312460187, createdTime=Sat Oct 29 08:40:04 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083547, encodeId=790c108354e11, content=偏重的研究方向：糖尿病 经验分享：最近我投了这个杂志，投稿14天已经有一个审稿意见回来了，感觉是不是要被拒了，有没有人分享经验？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2821418776, createdName=elisha1986922, createdTime=Thu Dec 23 15:06:01 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248658, encodeId=eaa41248658b9, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：氧化应激;糖尿病 经验分享：编辑很好，审稿也快，对SCI新手也很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a648175314, createdName=ms6000000147750690, createdTime=Tue Sep 13 15:04:17 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235020, encodeId=098012350207b, content=请问，录用到检索需要多久，有经验的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04ff6407559, createdName=ms2000000815129795, createdTime=Wed Jul 27 11:09:52 CST 2022, time=2022-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235628, encodeId=69dd12356286f, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：从投到最终接收不到五个月.编辑整体很nice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uLbZicGxVGAWXmCkrtzXibzr4ZBcjzaTNHjNnVEcERkDEgTeSeeHQtlg9mMhA5gbq1obJP80q1pYRxCgWUgTfQAQ/132, createdBy=04a75281899, createdName=runze4922, createdTime=Sat Jul 30 13:15:55 CST 2022, time=2022-07-30, status=1, ipAttribution=)]

2022-12-05 121a6c8dm38(暂无昵称) 来自广东省

审稿速度:3.0 | 投稿命中率:75.0
偏重的研究方向：糖尿病
经验分享：正在投稿中，等消息

32 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2099883, encodeId=58722099883aa, content=偏重的研究方向：代谢综合征 经验分享：1DA - WAITING FOR THIRD PARTY BILLING INFORMATION 请问大家，这个状态下收到的邮件，那个链接好像没有可以操作的东西，请问大家当时是怎么处理的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70e46545621, createdName=秃头医学僧, createdTime=Fri Nov 11 14:02:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102656, encodeId=ff8b210265635, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：大血管并发症;糖尿病 经验分享：经验分享：审稿比较快，投稿后1个月左右就返修了，编辑提出的意见很中肯而且一针见血，按照编辑的修改意见逐条进行修改后，很快就接收见刊了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8445702010, createdName=ms8000000933790308, createdTime=Fri Nov 25 22:07:57 CST 2022, time=2022-11-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2104368, encodeId=43f521043681e, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病 经验分享：正在投稿中，等消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=903a2271475, createdName=121a6c8dm38(暂无昵称), createdTime=Mon Dec 05 10:21:54 CST 2022, time=2022-12-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2103276, encodeId=9b1821032e6b6, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病并发症 经验分享：这次有四个审稿人，但是都非常nice，所有流程如下： 27 July 2022 Submission created 4 August 2022 Peer review selection 4 August 2022 Peer review invitations sent 5 August 2022 First peer reviewer allocated 7 August 2022 Two or more peer reviewers allocated 18 August 2022 First report returned 6 September 2022 Second or more peer reviewer reports returned 27 September 2022 Report sent to the Editor-in-Chief 28 September 2022 Report: revise with changes 30 September 2022 Resubmission pending 13 October 2022 Resubmitted manuscript received 18 October 2022 Processing revised manuscript 19 October 2022 Sent to Editor-in-Chief for acceptance or rejection 18 October 2022 Query regarding revised manuscript 20 October 2022 Invoice to follow for article processing charge subject to final decision 21 October 2022 Accepted for publication, invoice sent 21 October 2022 Payment has been received 25 October 2022 Manuscript sent to typesetter for pre-edit. No action required from the author 26 October 2022 Manuscript with the typesetter for first proof creation or updates to the proof. No action required from the author 27 October 2022 Typeset page proofs sent to the author(s) for correction or approval. Please login using the link provided to submit the proof back to Editorial team 27 October 2022 Author has returned corrections 29 October 2022 Page proofs approved by the author. At this point the manuscript is ready for publication 29 October 2022 Page proofs approved by the author. Paper is on hold awaiting further information 29 October 2022 Manuscript is sent for page numbering at Typesetter 29 October 2022 Manuscript been returned from Typesetter with page numbers 29 October 2022 Online final version is published, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221129/0e7eeda129144fbba505acd961d4e564/9a1914f121264b1dbf789fd21a61dab6.jpg, createdBy=a67a5253380, createdName=ms954663428435720, createdTime=Tue Nov 29 14:09:31 CST 2022, time=2022-11-29, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2107203, encodeId=0979210e203df, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病并发症;糖尿病 经验分享：已经连续发表两篇了，审稿者提问还是很中肯的，能为我们写作提供帮助。希望能涨涨分。不知道今年中科院分区怎么样。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2821418776, createdName=elisha1986922, createdTime=Fri Dec 23 21:03:46 CST 2022, time=2022-12-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2097212, encodeId=7627209e212c1, content=返修后从4C到7I只有3天时间，请问各位大神，7I是不是就悲剧了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2fb2950730, createdName=312460187, createdTime=Sat Oct 29 08:40:04 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083547, encodeId=790c108354e11, content=偏重的研究方向：糖尿病 经验分享：最近我投了这个杂志，投稿14天已经有一个审稿意见回来了，感觉是不是要被拒了，有没有人分享经验？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2821418776, createdName=elisha1986922, createdTime=Thu Dec 23 15:06:01 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248658, encodeId=eaa41248658b9, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：氧化应激;糖尿病 经验分享：编辑很好，审稿也快，对SCI新手也很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a648175314, createdName=ms6000000147750690, createdTime=Tue Sep 13 15:04:17 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235020, encodeId=098012350207b, content=请问，录用到检索需要多久，有经验的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04ff6407559, createdName=ms2000000815129795, createdTime=Wed Jul 27 11:09:52 CST 2022, time=2022-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235628, encodeId=69dd12356286f, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：从投到最终接收不到五个月.编辑整体很nice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uLbZicGxVGAWXmCkrtzXibzr4ZBcjzaTNHjNnVEcERkDEgTeSeeHQtlg9mMhA5gbq1obJP80q1pYRxCgWUgTfQAQ/132, createdBy=04a75281899, createdName=runze4922, createdTime=Sat Jul 30 13:15:55 CST 2022, time=2022-07-30, status=1, ipAttribution=)]

2022-11-29 ms954663428435720 来自江苏省

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：糖尿病并发症
经验分享：这次有四个审稿人，但是都非常nice，所有流程如下：
27 July 2022

Submission created

4 August 2022

Peer review selection

4 August 2022

Peer review invitations sent

5 August 2022

First peer reviewer allocated

7 August 2022

Two or more peer reviewers allocated

18 August 2022

First report returned

6 September 2022

Second or more peer reviewer reports returned

27 September 2022

Report sent to the Editor-in-Chief

28 September 2022

Report: revise with changes

30 September 2022

Resubmission pending

13 October 2022

Resubmitted manuscript received

18 October 2022

Processing revised manuscript

19 October 2022

Sent to Editor-in-Chief for acceptance or rejection

18 October 2022

Query regarding revised manuscript

20 October 2022

Invoice to follow for article processing charge subject to final decision

21 October 2022

Accepted for publication, invoice sent

21 October 2022

Payment has been received

25 October 2022

Manuscript sent to typesetter for pre-edit. No action required from the author

26 October 2022

Manuscript with the typesetter for first proof creation or updates to the proof. No action required from the author

27 October 2022

Typeset page proofs sent to the author(s) for correction or approval. Please login using the link provided to submit the proof back to Editorial team

27 October 2022

Author has returned corrections

29 October 2022

Page proofs approved by the author. At this point the manuscript is ready for publication

29 October 2022

Page proofs approved by the author. Paper is on hold awaiting further information

29 October 2022

Manuscript is sent for page numbering at Typesetter

29 October 2022

Manuscript been returned from Typesetter with page numbers

29 October 2022

Online final version is published

42 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2099883, encodeId=58722099883aa, content=偏重的研究方向：代谢综合征 经验分享：1DA - WAITING FOR THIRD PARTY BILLING INFORMATION 请问大家，这个状态下收到的邮件，那个链接好像没有可以操作的东西，请问大家当时是怎么处理的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70e46545621, createdName=秃头医学僧, createdTime=Fri Nov 11 14:02:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102656, encodeId=ff8b210265635, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：大血管并发症;糖尿病 经验分享：经验分享：审稿比较快，投稿后1个月左右就返修了，编辑提出的意见很中肯而且一针见血，按照编辑的修改意见逐条进行修改后，很快就接收见刊了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8445702010, createdName=ms8000000933790308, createdTime=Fri Nov 25 22:07:57 CST 2022, time=2022-11-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2104368, encodeId=43f521043681e, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病 经验分享：正在投稿中，等消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=903a2271475, createdName=121a6c8dm38(暂无昵称), createdTime=Mon Dec 05 10:21:54 CST 2022, time=2022-12-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2103276, encodeId=9b1821032e6b6, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病并发症 经验分享：这次有四个审稿人，但是都非常nice，所有流程如下： 27 July 2022 Submission created 4 August 2022 Peer review selection 4 August 2022 Peer review invitations sent 5 August 2022 First peer reviewer allocated 7 August 2022 Two or more peer reviewers allocated 18 August 2022 First report returned 6 September 2022 Second or more peer reviewer reports returned 27 September 2022 Report sent to the Editor-in-Chief 28 September 2022 Report: revise with changes 30 September 2022 Resubmission pending 13 October 2022 Resubmitted manuscript received 18 October 2022 Processing revised manuscript 19 October 2022 Sent to Editor-in-Chief for acceptance or rejection 18 October 2022 Query regarding revised manuscript 20 October 2022 Invoice to follow for article processing charge subject to final decision 21 October 2022 Accepted for publication, invoice sent 21 October 2022 Payment has been received 25 October 2022 Manuscript sent to typesetter for pre-edit. No action required from the author 26 October 2022 Manuscript with the typesetter for first proof creation or updates to the proof. No action required from the author 27 October 2022 Typeset page proofs sent to the author(s) for correction or approval. Please login using the link provided to submit the proof back to Editorial team 27 October 2022 Author has returned corrections 29 October 2022 Page proofs approved by the author. At this point the manuscript is ready for publication 29 October 2022 Page proofs approved by the author. Paper is on hold awaiting further information 29 October 2022 Manuscript is sent for page numbering at Typesetter 29 October 2022 Manuscript been returned from Typesetter with page numbers 29 October 2022 Online final version is published, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221129/0e7eeda129144fbba505acd961d4e564/9a1914f121264b1dbf789fd21a61dab6.jpg, createdBy=a67a5253380, createdName=ms954663428435720, createdTime=Tue Nov 29 14:09:31 CST 2022, time=2022-11-29, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2107203, encodeId=0979210e203df, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病并发症;糖尿病 经验分享：已经连续发表两篇了，审稿者提问还是很中肯的，能为我们写作提供帮助。希望能涨涨分。不知道今年中科院分区怎么样。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2821418776, createdName=elisha1986922, createdTime=Fri Dec 23 21:03:46 CST 2022, time=2022-12-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2097212, encodeId=7627209e212c1, content=返修后从4C到7I只有3天时间，请问各位大神，7I是不是就悲剧了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2fb2950730, createdName=312460187, createdTime=Sat Oct 29 08:40:04 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083547, encodeId=790c108354e11, content=偏重的研究方向：糖尿病 经验分享：最近我投了这个杂志，投稿14天已经有一个审稿意见回来了，感觉是不是要被拒了，有没有人分享经验？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2821418776, createdName=elisha1986922, createdTime=Thu Dec 23 15:06:01 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248658, encodeId=eaa41248658b9, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：氧化应激;糖尿病 经验分享：编辑很好，审稿也快，对SCI新手也很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a648175314, createdName=ms6000000147750690, createdTime=Tue Sep 13 15:04:17 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235020, encodeId=098012350207b, content=请问，录用到检索需要多久，有经验的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04ff6407559, createdName=ms2000000815129795, createdTime=Wed Jul 27 11:09:52 CST 2022, time=2022-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235628, encodeId=69dd12356286f, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：从投到最终接收不到五个月.编辑整体很nice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uLbZicGxVGAWXmCkrtzXibzr4ZBcjzaTNHjNnVEcERkDEgTeSeeHQtlg9mMhA5gbq1obJP80q1pYRxCgWUgTfQAQ/132, createdBy=04a75281899, createdName=runze4922, createdTime=Sat Jul 30 13:15:55 CST 2022, time=2022-07-30, status=1, ipAttribution=)]

2022-12-23 elisha1986922 来自上海

审稿速度:2.0 | 投稿命中率:95.0
偏重的研究方向：糖尿病并发症;糖尿病
经验分享：已经连续发表两篇了，审稿者提问还是很中肯的，能为我们写作提供帮助。希望能涨涨分。不知道今年中科院分区怎么样。

38 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2099883, encodeId=58722099883aa, content=偏重的研究方向：代谢综合征 经验分享：1DA - WAITING FOR THIRD PARTY BILLING INFORMATION 请问大家，这个状态下收到的邮件，那个链接好像没有可以操作的东西，请问大家当时是怎么处理的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70e46545621, createdName=秃头医学僧, createdTime=Fri Nov 11 14:02:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102656, encodeId=ff8b210265635, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：大血管并发症;糖尿病 经验分享：经验分享：审稿比较快，投稿后1个月左右就返修了，编辑提出的意见很中肯而且一针见血，按照编辑的修改意见逐条进行修改后，很快就接收见刊了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8445702010, createdName=ms8000000933790308, createdTime=Fri Nov 25 22:07:57 CST 2022, time=2022-11-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2104368, encodeId=43f521043681e, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病 经验分享：正在投稿中，等消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=903a2271475, createdName=121a6c8dm38(暂无昵称), createdTime=Mon Dec 05 10:21:54 CST 2022, time=2022-12-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2103276, encodeId=9b1821032e6b6, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病并发症 经验分享：这次有四个审稿人，但是都非常nice，所有流程如下： 27 July 2022 Submission created 4 August 2022 Peer review selection 4 August 2022 Peer review invitations sent 5 August 2022 First peer reviewer allocated 7 August 2022 Two or more peer reviewers allocated 18 August 2022 First report returned 6 September 2022 Second or more peer reviewer reports returned 27 September 2022 Report sent to the Editor-in-Chief 28 September 2022 Report: revise with changes 30 September 2022 Resubmission pending 13 October 2022 Resubmitted manuscript received 18 October 2022 Processing revised manuscript 19 October 2022 Sent to Editor-in-Chief for acceptance or rejection 18 October 2022 Query regarding revised manuscript 20 October 2022 Invoice to follow for article processing charge subject to final decision 21 October 2022 Accepted for publication, invoice sent 21 October 2022 Payment has been received 25 October 2022 Manuscript sent to typesetter for pre-edit. No action required from the author 26 October 2022 Manuscript with the typesetter for first proof creation or updates to the proof. No action required from the author 27 October 2022 Typeset page proofs sent to the author(s) for correction or approval. Please login using the link provided to submit the proof back to Editorial team 27 October 2022 Author has returned corrections 29 October 2022 Page proofs approved by the author. At this point the manuscript is ready for publication 29 October 2022 Page proofs approved by the author. Paper is on hold awaiting further information 29 October 2022 Manuscript is sent for page numbering at Typesetter 29 October 2022 Manuscript been returned from Typesetter with page numbers 29 October 2022 Online final version is published, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221129/0e7eeda129144fbba505acd961d4e564/9a1914f121264b1dbf789fd21a61dab6.jpg, createdBy=a67a5253380, createdName=ms954663428435720, createdTime=Tue Nov 29 14:09:31 CST 2022, time=2022-11-29, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2107203, encodeId=0979210e203df, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病并发症;糖尿病 经验分享：已经连续发表两篇了，审稿者提问还是很中肯的，能为我们写作提供帮助。希望能涨涨分。不知道今年中科院分区怎么样。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2821418776, createdName=elisha1986922, createdTime=Fri Dec 23 21:03:46 CST 2022, time=2022-12-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2097212, encodeId=7627209e212c1, content=返修后从4C到7I只有3天时间，请问各位大神，7I是不是就悲剧了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2fb2950730, createdName=312460187, createdTime=Sat Oct 29 08:40:04 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083547, encodeId=790c108354e11, content=偏重的研究方向：糖尿病 经验分享：最近我投了这个杂志，投稿14天已经有一个审稿意见回来了，感觉是不是要被拒了，有没有人分享经验？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2821418776, createdName=elisha1986922, createdTime=Thu Dec 23 15:06:01 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248658, encodeId=eaa41248658b9, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：氧化应激;糖尿病 经验分享：编辑很好，审稿也快，对SCI新手也很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a648175314, createdName=ms6000000147750690, createdTime=Tue Sep 13 15:04:17 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235020, encodeId=098012350207b, content=请问，录用到检索需要多久，有经验的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04ff6407559, createdName=ms2000000815129795, createdTime=Wed Jul 27 11:09:52 CST 2022, time=2022-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235628, encodeId=69dd12356286f, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：从投到最终接收不到五个月.编辑整体很nice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uLbZicGxVGAWXmCkrtzXibzr4ZBcjzaTNHjNnVEcERkDEgTeSeeHQtlg9mMhA5gbq1obJP80q1pYRxCgWUgTfQAQ/132, createdBy=04a75281899, createdName=runze4922, createdTime=Sat Jul 30 13:15:55 CST 2022, time=2022-07-30, status=1, ipAttribution=)]

2022-10-29 312460187

返修后从4C到7I只有3天时间，请问各位大神，7I是不是就悲剧了？

86 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2099883, encodeId=58722099883aa, content=偏重的研究方向：代谢综合征 经验分享：1DA - WAITING FOR THIRD PARTY BILLING INFORMATION 请问大家，这个状态下收到的邮件，那个链接好像没有可以操作的东西，请问大家当时是怎么处理的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70e46545621, createdName=秃头医学僧, createdTime=Fri Nov 11 14:02:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102656, encodeId=ff8b210265635, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：大血管并发症;糖尿病 经验分享：经验分享：审稿比较快，投稿后1个月左右就返修了，编辑提出的意见很中肯而且一针见血，按照编辑的修改意见逐条进行修改后，很快就接收见刊了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8445702010, createdName=ms8000000933790308, createdTime=Fri Nov 25 22:07:57 CST 2022, time=2022-11-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2104368, encodeId=43f521043681e, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病 经验分享：正在投稿中，等消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=903a2271475, createdName=121a6c8dm38(暂无昵称), createdTime=Mon Dec 05 10:21:54 CST 2022, time=2022-12-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2103276, encodeId=9b1821032e6b6, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病并发症 经验分享：这次有四个审稿人，但是都非常nice，所有流程如下： 27 July 2022 Submission created 4 August 2022 Peer review selection 4 August 2022 Peer review invitations sent 5 August 2022 First peer reviewer allocated 7 August 2022 Two or more peer reviewers allocated 18 August 2022 First report returned 6 September 2022 Second or more peer reviewer reports returned 27 September 2022 Report sent to the Editor-in-Chief 28 September 2022 Report: revise with changes 30 September 2022 Resubmission pending 13 October 2022 Resubmitted manuscript received 18 October 2022 Processing revised manuscript 19 October 2022 Sent to Editor-in-Chief for acceptance or rejection 18 October 2022 Query regarding revised manuscript 20 October 2022 Invoice to follow for article processing charge subject to final decision 21 October 2022 Accepted for publication, invoice sent 21 October 2022 Payment has been received 25 October 2022 Manuscript sent to typesetter for pre-edit. No action required from the author 26 October 2022 Manuscript with the typesetter for first proof creation or updates to the proof. No action required from the author 27 October 2022 Typeset page proofs sent to the author(s) for correction or approval. Please login using the link provided to submit the proof back to Editorial team 27 October 2022 Author has returned corrections 29 October 2022 Page proofs approved by the author. At this point the manuscript is ready for publication 29 October 2022 Page proofs approved by the author. Paper is on hold awaiting further information 29 October 2022 Manuscript is sent for page numbering at Typesetter 29 October 2022 Manuscript been returned from Typesetter with page numbers 29 October 2022 Online final version is published, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221129/0e7eeda129144fbba505acd961d4e564/9a1914f121264b1dbf789fd21a61dab6.jpg, createdBy=a67a5253380, createdName=ms954663428435720, createdTime=Tue Nov 29 14:09:31 CST 2022, time=2022-11-29, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2107203, encodeId=0979210e203df, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病并发症;糖尿病 经验分享：已经连续发表两篇了，审稿者提问还是很中肯的，能为我们写作提供帮助。希望能涨涨分。不知道今年中科院分区怎么样。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2821418776, createdName=elisha1986922, createdTime=Fri Dec 23 21:03:46 CST 2022, time=2022-12-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2097212, encodeId=7627209e212c1, content=返修后从4C到7I只有3天时间，请问各位大神，7I是不是就悲剧了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2fb2950730, createdName=312460187, createdTime=Sat Oct 29 08:40:04 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083547, encodeId=790c108354e11, content=偏重的研究方向：糖尿病 经验分享：最近我投了这个杂志，投稿14天已经有一个审稿意见回来了，感觉是不是要被拒了，有没有人分享经验？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2821418776, createdName=elisha1986922, createdTime=Thu Dec 23 15:06:01 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248658, encodeId=eaa41248658b9, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：氧化应激;糖尿病 经验分享：编辑很好，审稿也快，对SCI新手也很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a648175314, createdName=ms6000000147750690, createdTime=Tue Sep 13 15:04:17 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235020, encodeId=098012350207b, content=请问，录用到检索需要多久，有经验的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04ff6407559, createdName=ms2000000815129795, createdTime=Wed Jul 27 11:09:52 CST 2022, time=2022-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235628, encodeId=69dd12356286f, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：从投到最终接收不到五个月.编辑整体很nice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uLbZicGxVGAWXmCkrtzXibzr4ZBcjzaTNHjNnVEcERkDEgTeSeeHQtlg9mMhA5gbq1obJP80q1pYRxCgWUgTfQAQ/132, createdBy=04a75281899, createdName=runze4922, createdTime=Sat Jul 30 13:15:55 CST 2022, time=2022-07-30, status=1, ipAttribution=)]

2021-12-23 elisha1986922

偏重的研究方向：糖尿病
经验分享：最近我投了这个杂志，投稿14天已经有一个审稿意见回来了，感觉是不是要被拒了，有没有人分享经验？

66 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2099883, encodeId=58722099883aa, content=偏重的研究方向：代谢综合征 经验分享：1DA - WAITING FOR THIRD PARTY BILLING INFORMATION 请问大家，这个状态下收到的邮件，那个链接好像没有可以操作的东西，请问大家当时是怎么处理的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70e46545621, createdName=秃头医学僧, createdTime=Fri Nov 11 14:02:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102656, encodeId=ff8b210265635, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：大血管并发症;糖尿病 经验分享：经验分享：审稿比较快，投稿后1个月左右就返修了，编辑提出的意见很中肯而且一针见血，按照编辑的修改意见逐条进行修改后，很快就接收见刊了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8445702010, createdName=ms8000000933790308, createdTime=Fri Nov 25 22:07:57 CST 2022, time=2022-11-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2104368, encodeId=43f521043681e, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病 经验分享：正在投稿中，等消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=903a2271475, createdName=121a6c8dm38(暂无昵称), createdTime=Mon Dec 05 10:21:54 CST 2022, time=2022-12-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2103276, encodeId=9b1821032e6b6, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病并发症 经验分享：这次有四个审稿人，但是都非常nice，所有流程如下： 27 July 2022 Submission created 4 August 2022 Peer review selection 4 August 2022 Peer review invitations sent 5 August 2022 First peer reviewer allocated 7 August 2022 Two or more peer reviewers allocated 18 August 2022 First report returned 6 September 2022 Second or more peer reviewer reports returned 27 September 2022 Report sent to the Editor-in-Chief 28 September 2022 Report: revise with changes 30 September 2022 Resubmission pending 13 October 2022 Resubmitted manuscript received 18 October 2022 Processing revised manuscript 19 October 2022 Sent to Editor-in-Chief for acceptance or rejection 18 October 2022 Query regarding revised manuscript 20 October 2022 Invoice to follow for article processing charge subject to final decision 21 October 2022 Accepted for publication, invoice sent 21 October 2022 Payment has been received 25 October 2022 Manuscript sent to typesetter for pre-edit. No action required from the author 26 October 2022 Manuscript with the typesetter for first proof creation or updates to the proof. No action required from the author 27 October 2022 Typeset page proofs sent to the author(s) for correction or approval. Please login using the link provided to submit the proof back to Editorial team 27 October 2022 Author has returned corrections 29 October 2022 Page proofs approved by the author. At this point the manuscript is ready for publication 29 October 2022 Page proofs approved by the author. Paper is on hold awaiting further information 29 October 2022 Manuscript is sent for page numbering at Typesetter 29 October 2022 Manuscript been returned from Typesetter with page numbers 29 October 2022 Online final version is published, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221129/0e7eeda129144fbba505acd961d4e564/9a1914f121264b1dbf789fd21a61dab6.jpg, createdBy=a67a5253380, createdName=ms954663428435720, createdTime=Tue Nov 29 14:09:31 CST 2022, time=2022-11-29, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2107203, encodeId=0979210e203df, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病并发症;糖尿病 经验分享：已经连续发表两篇了，审稿者提问还是很中肯的，能为我们写作提供帮助。希望能涨涨分。不知道今年中科院分区怎么样。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2821418776, createdName=elisha1986922, createdTime=Fri Dec 23 21:03:46 CST 2022, time=2022-12-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2097212, encodeId=7627209e212c1, content=返修后从4C到7I只有3天时间，请问各位大神，7I是不是就悲剧了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2fb2950730, createdName=312460187, createdTime=Sat Oct 29 08:40:04 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083547, encodeId=790c108354e11, content=偏重的研究方向：糖尿病 经验分享：最近我投了这个杂志，投稿14天已经有一个审稿意见回来了，感觉是不是要被拒了，有没有人分享经验？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2821418776, createdName=elisha1986922, createdTime=Thu Dec 23 15:06:01 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248658, encodeId=eaa41248658b9, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：氧化应激;糖尿病 经验分享：编辑很好，审稿也快，对SCI新手也很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a648175314, createdName=ms6000000147750690, createdTime=Tue Sep 13 15:04:17 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235020, encodeId=098012350207b, content=请问，录用到检索需要多久，有经验的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04ff6407559, createdName=ms2000000815129795, createdTime=Wed Jul 27 11:09:52 CST 2022, time=2022-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235628, encodeId=69dd12356286f, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：从投到最终接收不到五个月.编辑整体很nice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uLbZicGxVGAWXmCkrtzXibzr4ZBcjzaTNHjNnVEcERkDEgTeSeeHQtlg9mMhA5gbq1obJP80q1pYRxCgWUgTfQAQ/132, createdBy=04a75281899, createdName=runze4922, createdTime=Sat Jul 30 13:15:55 CST 2022, time=2022-07-30, status=1, ipAttribution=)]

2022-09-13 ms6000000147750690

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：氧化应激;糖尿病
经验分享：编辑很好，审稿也快，对SCI新手也很友好

45 0

[GetPortalCommentsPageByObjectIdResponse(id=2099883, encodeId=58722099883aa, content=偏重的研究方向：代谢综合征 经验分享：1DA - WAITING FOR THIRD PARTY BILLING INFORMATION 请问大家，这个状态下收到的邮件，那个链接好像没有可以操作的东西，请问大家当时是怎么处理的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70e46545621, createdName=秃头医学僧, createdTime=Fri Nov 11 14:02:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102656, encodeId=ff8b210265635, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：大血管并发症;糖尿病 经验分享：经验分享：审稿比较快，投稿后1个月左右就返修了，编辑提出的意见很中肯而且一针见血，按照编辑的修改意见逐条进行修改后，很快就接收见刊了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8445702010, createdName=ms8000000933790308, createdTime=Fri Nov 25 22:07:57 CST 2022, time=2022-11-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2104368, encodeId=43f521043681e, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病 经验分享：正在投稿中，等消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=903a2271475, createdName=121a6c8dm38(暂无昵称), createdTime=Mon Dec 05 10:21:54 CST 2022, time=2022-12-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2103276, encodeId=9b1821032e6b6, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病并发症 经验分享：这次有四个审稿人，但是都非常nice，所有流程如下： 27 July 2022 Submission created 4 August 2022 Peer review selection 4 August 2022 Peer review invitations sent 5 August 2022 First peer reviewer allocated 7 August 2022 Two or more peer reviewers allocated 18 August 2022 First report returned 6 September 2022 Second or more peer reviewer reports returned 27 September 2022 Report sent to the Editor-in-Chief 28 September 2022 Report: revise with changes 30 September 2022 Resubmission pending 13 October 2022 Resubmitted manuscript received 18 October 2022 Processing revised manuscript 19 October 2022 Sent to Editor-in-Chief for acceptance or rejection 18 October 2022 Query regarding revised manuscript 20 October 2022 Invoice to follow for article processing charge subject to final decision 21 October 2022 Accepted for publication, invoice sent 21 October 2022 Payment has been received 25 October 2022 Manuscript sent to typesetter for pre-edit. No action required from the author 26 October 2022 Manuscript with the typesetter for first proof creation or updates to the proof. No action required from the author 27 October 2022 Typeset page proofs sent to the author(s) for correction or approval. Please login using the link provided to submit the proof back to Editorial team 27 October 2022 Author has returned corrections 29 October 2022 Page proofs approved by the author. At this point the manuscript is ready for publication 29 October 2022 Page proofs approved by the author. Paper is on hold awaiting further information 29 October 2022 Manuscript is sent for page numbering at Typesetter 29 October 2022 Manuscript been returned from Typesetter with page numbers 29 October 2022 Online final version is published, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221129/0e7eeda129144fbba505acd961d4e564/9a1914f121264b1dbf789fd21a61dab6.jpg, createdBy=a67a5253380, createdName=ms954663428435720, createdTime=Tue Nov 29 14:09:31 CST 2022, time=2022-11-29, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2107203, encodeId=0979210e203df, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病并发症;糖尿病 经验分享：已经连续发表两篇了，审稿者提问还是很中肯的，能为我们写作提供帮助。希望能涨涨分。不知道今年中科院分区怎么样。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2821418776, createdName=elisha1986922, createdTime=Fri Dec 23 21:03:46 CST 2022, time=2022-12-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2097212, encodeId=7627209e212c1, content=返修后从4C到7I只有3天时间，请问各位大神，7I是不是就悲剧了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2fb2950730, createdName=312460187, createdTime=Sat Oct 29 08:40:04 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083547, encodeId=790c108354e11, content=偏重的研究方向：糖尿病 经验分享：最近我投了这个杂志，投稿14天已经有一个审稿意见回来了，感觉是不是要被拒了，有没有人分享经验？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2821418776, createdName=elisha1986922, createdTime=Thu Dec 23 15:06:01 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248658, encodeId=eaa41248658b9, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：氧化应激;糖尿病 经验分享：编辑很好，审稿也快，对SCI新手也很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a648175314, createdName=ms6000000147750690, createdTime=Tue Sep 13 15:04:17 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235020, encodeId=098012350207b, content=请问，录用到检索需要多久，有经验的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04ff6407559, createdName=ms2000000815129795, createdTime=Wed Jul 27 11:09:52 CST 2022, time=2022-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235628, encodeId=69dd12356286f, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：从投到最终接收不到五个月.编辑整体很nice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uLbZicGxVGAWXmCkrtzXibzr4ZBcjzaTNHjNnVEcERkDEgTeSeeHQtlg9mMhA5gbq1obJP80q1pYRxCgWUgTfQAQ/132, createdBy=04a75281899, createdName=runze4922, createdTime=Sat Jul 30 13:15:55 CST 2022, time=2022-07-30, status=1, ipAttribution=)]

2022-07-27 ms2000000815129795

请问，录用到检索需要多久，有经验的小伙伴吗？

44 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2099883, encodeId=58722099883aa, content=偏重的研究方向：代谢综合征 经验分享：1DA - WAITING FOR THIRD PARTY BILLING INFORMATION 请问大家，这个状态下收到的邮件，那个链接好像没有可以操作的东西，请问大家当时是怎么处理的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70e46545621, createdName=秃头医学僧, createdTime=Fri Nov 11 14:02:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102656, encodeId=ff8b210265635, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：大血管并发症;糖尿病 经验分享：经验分享：审稿比较快，投稿后1个月左右就返修了，编辑提出的意见很中肯而且一针见血，按照编辑的修改意见逐条进行修改后，很快就接收见刊了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8445702010, createdName=ms8000000933790308, createdTime=Fri Nov 25 22:07:57 CST 2022, time=2022-11-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2104368, encodeId=43f521043681e, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病 经验分享：正在投稿中，等消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=903a2271475, createdName=121a6c8dm38(暂无昵称), createdTime=Mon Dec 05 10:21:54 CST 2022, time=2022-12-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2103276, encodeId=9b1821032e6b6, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病并发症 经验分享：这次有四个审稿人，但是都非常nice，所有流程如下： 27 July 2022 Submission created 4 August 2022 Peer review selection 4 August 2022 Peer review invitations sent 5 August 2022 First peer reviewer allocated 7 August 2022 Two or more peer reviewers allocated 18 August 2022 First report returned 6 September 2022 Second or more peer reviewer reports returned 27 September 2022 Report sent to the Editor-in-Chief 28 September 2022 Report: revise with changes 30 September 2022 Resubmission pending 13 October 2022 Resubmitted manuscript received 18 October 2022 Processing revised manuscript 19 October 2022 Sent to Editor-in-Chief for acceptance or rejection 18 October 2022 Query regarding revised manuscript 20 October 2022 Invoice to follow for article processing charge subject to final decision 21 October 2022 Accepted for publication, invoice sent 21 October 2022 Payment has been received 25 October 2022 Manuscript sent to typesetter for pre-edit. No action required from the author 26 October 2022 Manuscript with the typesetter for first proof creation or updates to the proof. No action required from the author 27 October 2022 Typeset page proofs sent to the author(s) for correction or approval. Please login using the link provided to submit the proof back to Editorial team 27 October 2022 Author has returned corrections 29 October 2022 Page proofs approved by the author. At this point the manuscript is ready for publication 29 October 2022 Page proofs approved by the author. Paper is on hold awaiting further information 29 October 2022 Manuscript is sent for page numbering at Typesetter 29 October 2022 Manuscript been returned from Typesetter with page numbers 29 October 2022 Online final version is published, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221129/0e7eeda129144fbba505acd961d4e564/9a1914f121264b1dbf789fd21a61dab6.jpg, createdBy=a67a5253380, createdName=ms954663428435720, createdTime=Tue Nov 29 14:09:31 CST 2022, time=2022-11-29, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2107203, encodeId=0979210e203df, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病并发症;糖尿病 经验分享：已经连续发表两篇了，审稿者提问还是很中肯的，能为我们写作提供帮助。希望能涨涨分。不知道今年中科院分区怎么样。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2821418776, createdName=elisha1986922, createdTime=Fri Dec 23 21:03:46 CST 2022, time=2022-12-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2097212, encodeId=7627209e212c1, content=返修后从4C到7I只有3天时间，请问各位大神，7I是不是就悲剧了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2fb2950730, createdName=312460187, createdTime=Sat Oct 29 08:40:04 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083547, encodeId=790c108354e11, content=偏重的研究方向：糖尿病 经验分享：最近我投了这个杂志，投稿14天已经有一个审稿意见回来了，感觉是不是要被拒了，有没有人分享经验？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2821418776, createdName=elisha1986922, createdTime=Thu Dec 23 15:06:01 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248658, encodeId=eaa41248658b9, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：氧化应激;糖尿病 经验分享：编辑很好，审稿也快，对SCI新手也很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a648175314, createdName=ms6000000147750690, createdTime=Tue Sep 13 15:04:17 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235020, encodeId=098012350207b, content=请问，录用到检索需要多久，有经验的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04ff6407559, createdName=ms2000000815129795, createdTime=Wed Jul 27 11:09:52 CST 2022, time=2022-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235628, encodeId=69dd12356286f, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：从投到最终接收不到五个月.编辑整体很nice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uLbZicGxVGAWXmCkrtzXibzr4ZBcjzaTNHjNnVEcERkDEgTeSeeHQtlg9mMhA5gbq1obJP80q1pYRxCgWUgTfQAQ/132, createdBy=04a75281899, createdName=runze4922, createdTime=Sat Jul 30 13:15:55 CST 2022, time=2022-07-30, status=1, ipAttribution=)]

2022-07-30 runze4922

审稿速度:2.0 | 投稿命中率:75.0
经验分享：从投到最终接收不到五个月.编辑整体很nice

45 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务